Phospho-BLNK (Tyr84) (H4) rabbit mAb

www.abwizbio.com
Support: info@abwizbio.com
Order: sales@abwizbio.com

Catalog: #2291

Store at: -20ºC

For Research Use Only. Not For Use In Diagnostic Procedures.

Applications	Detection	Clonality	Isotype
Flow Cytometry	Anti-Rabbit IgG	Monoclonal	Rabbit IgGk

Format: Unconjugated

Cross Reactivity: Predicted to work with mouse, rat and other homologues.

Formulation: 1X PBS, 0.02% NaN3, 50% Glycerol, 0.1% BSA

Preparation: Protein A+G

Reactivity: Human

Recommended Usage: 1µg/mL – 0.001µg/mL. It is recommended that the reagent be titrated for optimal performance for each application. See product image legends for additional information.

Immunogen: A synthetic phospho-peptide corresponding to residues surrounding Tyr84 of human phospho BLNK

Description: BLNK protein, known as SLP-65 play an important role as adaptor protein in B-lineage cells. BLNK associates with proteins in the cytoplasmic side of plasma membrane through its N-terminal leucine zipper motif. Upon BLNK activation on its tyrosine, BLNK binds to Btk, Vav, Brb2, Syk, and HPK1. Through this associations, BLNK mediates Ca2+ mobilization, for ERK1/2, JNK and p38 MAP kinase activation. After phosphorylation, BLNK binds Btk and PLCγ2 through their SH2 domains and mediates PLCγ2 activation by Btk. BLNK also binds other signaling molecules such as Vav, Grb2, Syk, and HPK1. BLNK plays aa important role in BCR-dependent progression of B cell development, BCR-mediated B cell survival, activation, proliferation, and T-independent immune responses.

References:

Fu, C., et al. (1998) Immunity 9: 93–103.
Goitsuka, R., et al. (1998) J. Immunol. 161: 5804–5808.
Tsuji, S., et al. (2001) J. Exp. Med. 194: 529–539.



	IgG	Treatment	Peptide Block	Median : BL1-A
	H4	IFNa	Non-phos	88579
	H4	Ctrl	Non-phos	2748
	H4	IFNa	Phos	700
	H4	Ctrl	Phos	343
	H4	IFNa	-	75009
	H4	Ctrl	-	4167
	2' only	Ctrl	-	352

Peptide blocking flow cytometric analysis of Daudi cells secondary antibody only negative control (light blue) or untreated (red) or with IFNα + IL-4 + pervanadate (green) or untreated and blocked with phospho-peptide (black) or treated and blocked with phospho peptide (gold) or untreated and blocked with non-phospho peptide (dark blue) or treated and blocked with non-phospho peptide (purple) using Phospho-BLNK (Tyr84) antibody BLNKY84-H4 at 0.01 µg/mL. Cat. #2291.



Flow cytometric analysis of Daudi cells secondary antibody only negative control (blue) or untreated (red) or treated with IFNα + IL-4 + pervanadate (green) using Phospho-BLNK (Tyr84) antibody BLNKY84-H4 at 0.01 µg/mL. Cat. #2291.



Flow cytometric analysis of Daudi cells secondary antibody only negative control (blue) or untreated (red) or treated with IFNa + IL-4 + pervanadate (green) using 10 ng/mL of Phospho-BLNK (Tyr84) antibody BLNKY84-H4 (Abwiz Cat. #2291) or Company B antibody at 2.5 ug/mL (manufacturer's recommended concentration).